-- 根據週三提交給上海證券交易所的公告，江蘇東方盛虹（SHE:000301）預計2025年將實現歸屬於股東的盈利1.337億元人民幣，而2024年則虧損23億元人民幣。 這家石化和新型化學生產商的每股收益達到0.02元人民幣，而去年同期每股虧損0.35元。 營業收入較去年同期下降8.8%，從1,377億元降至1,256億元。
Related Articles
Asia
CGS's Profit Climbs 10% in Q1
China Galaxy Securities (HKG:6881, SHA:601881) or CGS recorded a 10% rise in attributable profit in the first quarter of 2026 to 3.32 billion yuan from 3.02 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The securities broker's earnings per share rose to 0.28 yuan from 0.25 yuan in the corresponding period of the previous fiscal year.Operating income increased 16% to 7.35 billion yuan from 6.36 billion yuan after adjustment in the year-ago period.
$HKG:6881$SHA:601881
Asia
Indian Equities End Higher on Wednesday Amid Positive Fiscal Q4 Earnings
Indian benchmark indices ended higher on Wednesday, supported by positive fiscal Q4 earnings and value buying across select sectors.A large part of intraday gains was, however, trimmed in late trade due to profit booking.The BSE Sensex rose 609.45 points, or 0.8%, to close at 77,496.36, while the NSE Nifty 50 gained 181.95 points, or also 0.8%, to settle at 24,177.65.The market saw early support from selective buying, especially in auto stocks, which helped indices move higher in morning trade. However, the momentum was lost later as investors locked in gains at higher levels.Rising crude oil prices also kept sentiment in check amid concerns about supply disruptions if the Strait of Hormuz remains closed for longer period.Among stocks, Vedanta (NSE:VEDL, BOM:500295) rose nearly 5% after reporting a sharp jump in fiscal Q4 profit to 67.0 billion rupees from 34.8 billion rupees a year earlier.Shelter Pharma (BOM:543963) gained nearly 4% after securing a $144,000 export order for pharmaceutical supplies.
$^BSE$^NSEI$BOM:500295$BOM:543963$NSE:VEDL
International